Article
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.
All News
Article
A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).
Dr. John Cush
Tweet
Potent Topical Corticosteroids and the Risk of Osteoporotic Fractures
https://t.co/OHohMKveik
Dr. John Cush
Tweet
#RNL2021
Thanks @uptoTate https://t.co/VKFodPOwgC
Dr. John Cush
Tweet
#RNL2021 coverage by @uptoTate for #RheumNow https://t.co/x1GjGGNPii
Dr. John Cush
Tweet
Great #RNL2021 coverage by @KDAO2011 for #RheumNow https://t.co/GBnlyvPaz1
Dr. John Cush
Tweet
Liver Management in RA - #RNL2021 Highlight by @DrPetryna
While RA is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the mgmt of many RA patients.
https://t.co/OeuloDIXMF
Dr. John Cush
Tweet
New RheumNow Podcast Now Available!
Infection in ANCA-Associated Vasculitis
https://t.co/Twy04G9RU1
Download wherever podcasts are available!
Dr. John Cush
Tweet
RheumNow Podcast – Infection in ANCA-Associated Vasculitis
Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on https://t.co/4GKxMY5Lll
https://t.co/joi1puBSuX
Dr. John Cush
Tweet
#RNL2021 coverage from @KDAO2011 #RheumNow https://t.co/GBnlyvPaz1
Dr. John Cush
Tweet
Are You a Super Rheum?
https://t.co/omvQXwhcoV https://t.co/8iQaRAi5di
Dr. John Cush
Tweet
Analysis of CPRD registry and 15670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY; half that after Yr 1 (22 & 2.84). D/C for severe labs was 1 in 169 Yr1 & 1 in 352 per year after https://t.co/Dx91YqjplT
Dr. John Cush
Tweet
#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned
https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D
Dr. John Cush
Tweet
News Feature: FDA Panel Rejects Tanezumab for Osteoarthritis
A 2 day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab for use in OA.
https://t.co/ltKmm9Nl1y https://t.co/qTWhSX9LBd
Dr. John Cush
Tweet
The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease
Sponsored by Novartis Medical Affairs
Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020.
View Now: https://t.co/Kp2drDAqFv https://t.co/tjkUpxcMdT
Dr. John Cush
Tweet
#RNL2021 coverage from @uptoTate #RheumNow https://t.co/u11ltNc2vA
Dr. John Cush
Tweet
The RheumNow podcast is up--Great Associations
Dr. Jack Cush rants on the journal reports, news and FDA actions featured last week on RheumNow.
https://t.co/gzWVbL8xMJ
Dr. John Cush
Tweet
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo
Dr. John Cush
Tweet
Dr. John Cush
Tweet
News Feature: Safety of Paternal DMARD or Biologic Use
https://t.co/9jCNJ9rHYF https://t.co/SIRPcPQxyB
